NASDAQ: CAPR: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Capricor Therapeutics, Inc

Impact · against what's priced in

The filing of a class action lawsuit is a secondary negative development following the catastrophic 64% drop in stock price triggered by FDA briefing documents. While the lawsuit adds legal liability, the primary value destruction has already occurred due to the FDA's unfavorable benefit-risk assessment of deramiocel.

CAPR−0.20

No priced-in read yet